To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials (RCT), matched-control, case series, and case report studies. Random-effects analyses of RCT data demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
- Convalescent plasma
- Coronavirus disease 2019 (COVID-19)
- Passive antibody therapy
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ASJC Scopus subject areas